Table 3.

Association between SLC2A1 gene variants and T2DM- nephropathy for the additive and co-dominant models.

Variant	Genetic model	OR (95% CI)	*p-Value	ORadj. (95% CI)	#p-Value
rs12407920 C/T	Additive	0.92 (0.15–5.56)	0.926	0.69 (0.09-5.02)	.715
	Co-dominant	2.01 (1.17–3.45)	0.010	1.98 (1.14–3.43)	.015
rs2297976 G/T	Additive	1.25 (0.43–3.67)	0.679	1.17 (0.39–3.47)	.778
	Co-dominant	0.94 (0.63–1.40)	0.755	0.92 (0.61–1.38)	.677
rs710221 G/A	Additive	1.08 (0.61–1,88)	0.795	1.01 (0.56–1.81)	.987
	Co-dominant	0.86 (0.58–1.26)	0.432	0.85 (0.58–1.26)	.425
rs2086856 A/G	Additive	1.77 (0.92–3.40)	0.089	1.85 (0.94–3.65)	.075
	Co-dominant	0.86 (0.59–1.26)	0.441	0.85 (0.58–1.26)	.452
rs12130264 C/T	Additive	2.37 (0.21–26,41)	0.482	2.81 (0.25–31,79)	.403
	Co-dominant	0.67 (0.36 1.25)	0.209	0.72 (0.38–1.38)	.327
rs841847 C/T	Additive	1.80 (0.90–3.62)	0.097	1.77 (0.84–3.70)	.131
	Co-dominant	1.73 (1.17–2.56)	0.006	1.73 (1.16–2.58)	.007
rs841853 C/A	Additive	1.80 (0.95–3.40)	0.070	1.85 (0.94–3.61)	.073
	Co-dominant	1.74 (1.18–2.55)	0.005	1.75 (1.18–2.58)	.005
rs3729548 C/T	Additive	0.52 (0.29–0.90)	0.021	0.50 (0.28–0.92)	.025
	Co-dominant	1.07 (0.73–1.56)	0.737	1.06 (0.72–1.56)	.778
rs841855 G/A	Additive	1.09 (0.33–3,66)	0.887	1.04 (0.31–3.55)	.948
	Co-dominant	1.10 (0.72–1.69)	0.644	1.12 (0.73–1.73)	.608
rs3768029 C/T	Additive	0.66 (0.38–1.14)	0.135	0.65 (0.37–1,16)	.146
	Co-dominant	1.26 (0.86–1.84)	0.233	1.29 (0.87–1,90)	.202
rs12071418 C/G	Additive	**n.a.	**n.a.	**n.a.	**n.a.
	Co-dominant	0.61 (0.18–2.06)	0.427	0.59 (0.17–2.01)	.396
rs3820549 C/G	Additive	0.99 (0.51–1.95)	0.988	0.99 (0.50–1.99)	.987
	Co-dominant	0.89 (0.61–1,32)	0.571	0.88 (0.59–1.30)	.517
rs3820546 G/A	Additive	0.84 (0.48–1.46)	0.534	0.85 (0.48–1,50)	.577
	Co-dominant	1.46 (0.99–2.14)	0.052	1.35 (0.92–2.00)	.126
rs11537641 G/A	Additive	0.40 (0.13–1.28)	0.125	0.36 (0.11–1,17)	.089
	Co-dominant	1.05 (0.69–1.59)	0.819	1.03 (0.68–1.58)	.874

Odds Ratio (OR) and the corresponding 95% Confidence Intervals (CI) for testing the association between the SLC2A1 gene variants and T2DM-nephropathy for the additive and co-dominant models. The ORs adjusted for age and sex calculated by univariate logistic regression are also shown. In all variants, the ORs are calculated considering the heterozygote as the risk genotype for the co-dominant model and the minor allele as the risk allele for the additive model.

^*χ²p Values.

^#Multivariate logistic regression p values.

^**Not applicable, because there are no G allele homozygotes. OR and p values are in bold in case of statistical significance.